Corvus Pharmaceuticals, Inc. ( CRVS ) lead asset would have to be soquelitinib. It's an investigational oral small-molecule drug being developed by Corvus. It's been seen to selectively inhibit interleukin-2–inducibleI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation fo ...

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.Shares of Netflix Inc (NASDAQ:NFLX) fell sharply in pre-market trading after the company reported fourth-quarter financial results and issued first-quarter guidance below estimates.Netflix reported better-than-expected fourth-quarter financial results Tuesday after market close. Netflix said it sees first-quarter revenue of $12.16 billion versus a Street consensus estimate of $12.19 billion, according to data f ...

格隆汇1月21日丨CORVUS制药(CRVS.US)盘前跌超10%，此前该公司启动了1.5亿股股票发行。 ...

Barclays maintains an "Overweight" rating for CRVS, raising its price target from $16 to $28.CRVS announced a $150 million public offering to fund working capital and corporate purposes.Positive Phase 1 trial data for soquelitinib shows strong efficacy and safety, doubling CRVS stock price.Corvus Pharmaceuticals (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, focusing on developing innovative therapies for immune-related diseases. Recently, Barclays maintained an " ...

Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic dermatitis (eczema) showed strong efficacy and clean safety, and investors are watching further development of the eczema program.Trading volume reached 82 million shares, about 3,032% above its three-month average of 2.6 million shares. Corvus Pharmaceuticals IPO'd in 2016 and has dropped 44% since going public. How ...

Company Overview - Corvus Pharmaceuticals (NASDAQ:CRVS) is a small biotech company focused on developing innovative treatments for various medical conditions, particularly eczema [1] - The company has a market capitalization of approximately $1.36 billion, reflecting its growing presence in the biotech industry [4][5] Stock Performance - The stock price of CRVS is currently at $18.20, marking a significant increase of 126.09% with a change of $10.15 [3] - The stock has fluctuated between a low of $12.69 and a high of $19.12 today, with $19.12 being its highest price for the year [3] - Recently, the stock reached an eight-year high following the release of promising eczema treatment results [2][5] Analyst Insights - Sean Lee from H.C. Wainwright set a new price target of $27 for CRVS, indicating a potential increase of approximately 48.19% from its current trading price of $18.22 [2][5] - The trading volume for the day is 54.94 million shares, indicating strong investor interest and confidence in the company's potential impact in the biotech sector [4][5]

PresentationGood morning, everyone. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Conference Call. [Operator Instructions] It is now my pleasure to turn the call over to Zack Kubow of Real Chemistry. Please go ahead, sir.Zack KubowReal Chemistry, Inc. Thank you, operator, and good morning, everyone. Thanks for joining us today on the call. This conference call is being webcast with presentation slides. We encourage participants to join the webcast in order to view the slides. You can ...

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the offering will be offered by Corvus. In addition, Corvus e ...

Core Insights - Corvus Pharmaceuticals' shares more than doubled on January 20 following the announcement of positive Phase 1 trial data for its oral investigational drug, soquelitinib, aimed at treating atopic dermatitis [1] Company Summary - The significant increase in share price indicates strong investor confidence in the potential of soquelitinib as a treatment option for atopic dermatitis [1] - The positive trial results may position Corvus Pharmaceuticals favorably in the competitive dermatology market, particularly for conditions like atopic dermatitis [1]

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) on Tuesday shared data from cohort 4 of the Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis.In reaction to the positive data, Corvus Pharmaceuticals’ stock is trading higher with a session volume of 30.79 million compared to the average volume of 1.33 million.The cohort 4 data demonstrated favorable safety and efficacy results consistent with those from cohorts 1-3, including a deeper response in cohort 4 over the 8-week ...